Related Experiment Video
Updated: Apr 16, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
CB1 cannabinoid receptor ligands
Ganesh A Thakur1, Spyros P Nikas, Alexandros Makriyannis
1Center for Drug Discovery, University of Connecticut, Storrs, 06269, USA.
Abstract:
The CB1 receptor is expressed in the central nervous system and numerous other tissues including heart, lung and uterus and has been recognized as an important therapeutic target for pain, appetite modulation, glaucoma, multiple sclerosis and other indications. An interesting feature of this GPCR is its ability to be activated by a number of structurally different classes of compounds, thus, raising the possibility of multiple activated forms of the receptor. Understanding of the structure-activity relationships of cannabinergic ligands has paved the road for the development of novel ligands exhibiting receptor subtype selectivity and efficacy. This review highlights the important CB1 cannabinergic ligands developed to date.
Related Concept Videos
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Opioid Receptors: Overview
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...

